1. Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH (2007) Kosteneffektivität der Psoriasisbehandlung mit Etanercept in Deutschland [Cost-effectiveness of psoriasis therapy with etanercept in Germany]. JDDG 5:762–769
2. Mittendorf T (2010) Current reforms in pricing and reimbursement in Germany: implications for the pharmaceutical industry. ISPOR Connections 16(6): Nov–Dec
3. Neilson AR, Sieper J, Deeg M (2010) Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. Rheumatology 49:2122–2134
4. Runge C (2012) Separating the wheat from the chaff. Eur J Health Econ 13:121–126
5. Seifert C, Lottmann K, Chen X, Gultyaev D, Rosenfeld S, Schädlich PK, Müller E (2011) Budget-impact-Analyse von Dronedaron bei Behandlung von Patienten mit nicht-permanentem Vorhofflimmern aus perspektive der GKV in Deutschland [Budget impact analysis of dronedarone for the management of atrial fibrillation from the perspective of the German Statutory Health Insurance]. Perfusion 24:212–220